G01N 2333/56
Ifn-alpha
Official title: IFN-alpha
G01N2333/56 (Ifn-alpha) appears on 26 US grants and 62 published applications in this corpus.
Search patents in G01N- Granted patents
- 26
- Published applications
- 62
- Assignees
- 42
- Inventors
- 128
- Latest grant
- 6 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 2 |
| 2003 | 0 | 3 |
| 2004 | 1 | 2 |
| 2005 | 0 | 2 |
| 2006 | 1 | 2 |
| 2007 | 0 | 3 |
| 2008 | 0 | 1 |
| 2009 | 1 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 2 |
| 2012 | 0 | 3 |
| 2013 | 2 | 2 |
| 2014 | 0 | 0 |
| 2015 | 2 | 4 |
| 2016 | 0 | 5 |
| 2017 | 0 | 3 |
| 2018 | 1 | 3 |
| 2019 | 4 | 3 |
| 2020 | 1 | 5 |
| 2021 | 2 | 6 |
| 2022 | 1 | 2 |
| 2023 | 2 | 1 |
| 2024 | 3 | 3 |
| 2025 | 3 | 2 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method for measuring systemic chronic inflammaging6 Jan 2026US 12,517,135 B2Edifice Health, Inc.
- Quantitative biomarkers of EHV-1 susceptibility and protection8 Jul 2025US 12,352,758 B2Cornell University
- Biomarkers related to organ function25 Mar 2025US 12,259,397 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer18 Feb 2025US 12,227,577 B2Merck Patent GmbH
- Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases3 Dec 2024US 12,157,772 B2National Center of Neurology and Psychiatry
- Systemic biomarkers for the dynamic assessment of tumor burden and treatment efficacy in high grade gliomas2 Jul 2026US 2026/0188489 A1Mary Hitchcock Memorial Hospital, for itself and on behalf of Dartmouth-Hitchcock Clinic
- Unique Interferon Alpha 2B And New Method Of Making Thereof18 Jun 2026US 2026/0167690 A1PharmaEssentia Corp.
- Method of characterizing tumors17 Jul 2025US 2025/0231177 A1University of Florida Research Foundation, Inc.
- Multiplex cellular assays for screening and quality assessment of engineered cells23 Jan 2025US 2025/0027133 A1Cellanome, Inc.
- Anti-pd1 therapy based on response to ifn-i stimulation26 Dec 2024US 2024/0426810 A1University Health Network
Most cited
By later US patents
- Anti-interferon-α antibodies24US 7,087,726 B2Genentech, Inc. · 2006
- Monoclonal antibodies to type I interferon receptor18US 6,713,609 B1Genentech, Inc. · 2004
- Anti-interferon-α antibodies12US 7,582,445 B2Genentech, Inc. · 2009
- Human anti-IFN-α antibodies4US 10,112,995 B2ImmunoQure AG · 2018
- Anti-interferon-α antibodies4US 7,910,707 B2Genentech, Inc. · 2011